Bile-acid 7α-dehydroxylation is a gut-microbial bile-acid transformation encoded by the bai operon; the report cites Devlin & Fischbach (2015), “A biosynthetic pathway for a prominent class of microbiota-derived bile acids” (Nat Chem Biol 11(9):685–690, PMID: 26412091), as the mechanism in clostridium-scindens-like bacteria and as the anchor for its NB09c bile-acid network finding 1.
Aliases in the corpus: “7α-dehydroxylation”, “BA 7α-dehydroxylation”, “bai-operon activity”. The project attributes the activity to core bai-operon genes that are, in its own wording, “presumably present in essentially all F. plautii strains” — a presumption asserted in the report rather than a measurement made in it, so the core-rather-than-strain-variable status of the pathway is not established here 1.
Active and inactive taxa
The central digest classifies flavonifractor plautii, eggerthella lenta and enterocloster bolteae as taxa that actively 7α-dehydroxylate, while mediterraneibacter gnavus and escherichia-coli do not, and warns that depleting active 7α-dehydroxylators shifts the bile-acid pool toward inflammatory primary tauro-conjugated forms — a “bile-acid coupling cost” of targeting a pathobiont 2.
The underlying project reports the discriminating pattern directly: M. gnavus and E. coli show the opposite association structure — positive with primary tauro-conjugated bile acids, negative with secondary bile acids — and were therefore not assigned to the 7α-dehydroxylation network 1. This supports the active/inactive split above with a within-project, measurement-level null for the two inactive taxa 2,1.
Cross-corroborated evidence chain
The bile-acid claim is one of two independent six-line cross-corroboration narratives built from a single dataset, each demonstrating the same biological claim across analytical granularities. The bile-acid line runs: within-carrier pathway differential abundance (DA — testing whether a feature differs in abundance between groups) → subject-level metabolite DA → paired sample-level direct substrate-product signature → strain-level informative null → mechanism literature 2.
A methodological caveat qualifies where that chain’s weight sits: bile-acid pool sizes vary across cohorts because of dietary and antibiotic confounding, but the mechanistic substrate-product signature for active 7α-dehydroxylation is preserved at the within-paired-sample level. The NB09c narrative is therefore anchored on paired sample-level evidence plus the literature mechanism, not on cohort-aggregate DA replication; the report treats cohort-aggregate cross-cohort DA and within-cohort paired-sample correlation as different evidence streams, one of which can be weaker without invalidating the other 1.
At the metabolite level, only 3 of 21 bile-acid-theme metabolites were CD-up (CD — Crohn’s disease): free taurine, tauro-α-muricholate and tauro-β-muricholate. Free taurine, the conjugating amino acid rather than a bile acid, is CD-up at cliff=+0.47, and tauro-α/β-muricholate — a primary tauro-conjugated bile acid — is CD-up at +0.40. The report reads this as consistent with reduced microbial bile-acid 7α-dehydroxylation in Crohn’s disease, where primary tauro-conjugated bile acids accumulate when F. plautii / C. scindens / Eggerthellaceae dehydroxylation activity is impaired, and as corroborating F. plautii’s mechanistic role 1. See metabolite-class-signatures-of-gut-inflammation.
The external anchor is franzosa et al. (2019), “Gut microbiome structure and metabolic activity in inflammatory bowel disease” (Nat Microbiol 4(2):293–305, PMID: 30531976), an hmp2 metabolomics plus microbiome integration described as the canonical bile-acid 7α-dehydroxylation deficit together with polyamine and lipid signatures in inflammatory bowel disease 1.
Species abundance versus strain content
The digest records zero strain-adaptation gene signal in the Kumbhari cohort and reads the association as species-abundance-mediated rather than strain-content-mediated — phage targeting would then produce predictable activity depletion with no within-species strain-content escape route 2. The project scopes that null to one species: it reports zero strain-adaptation genes at FDR<0.10 (FDR — false discovery rate, the multiple-testing-adjusted significance threshold) for F. plautii, out of 3,245 genes total tested in F. plautii, while the same Kumbhari analysis did recover niche-adaptation gene signals in other species, with top gene symbols consistent across 9-10 species each 1.
The project’s own interpretation rests on the presumptive genomic premise noted above: F. plautii CD-association is said to operate through species-level abundance rather than strain-level genomic adaptation because the 7α-dehydroxylation activity is encoded by core bai-operon genes presumably present in essentially all F. plautii strains, so the CD signal reflects how much F. plautii (any strain) is present rather than which strain dominates 1. Because the pan-strain presence of bai is assumed rather than measured, the “no strain-content escape route” reading suggests the hypothesis that phage depletion removes the activity with it, rather than an established finding 2,1.
Design consequence for phage cocktails
Bile-acid 7α-dehydroxylation centred on F. plautii / E. lenta / E. bolteae and iron acquisition centred on E. coli AIEC (adherent-invasive E. coli) are proposed as two cross-corroborated six-line mechanism narratives sitting within one unified axis as orthogonal molecular sub-mechanisms 1. The iron side is developed in iron acquisition and pathobiont expansion; the bile-acid side supplies the cost term in ecological-cost-of-microbiome-target-depletion.
F. plautii’s bile-acid coupling cost is called the dominant E1 design constraint: it is present in 78 % of patients including all 9 E1 patients, and carries the highest BA-coupling cost (NB09c §13) together with a Pillar-4 phage gap (NB12) — a double penalty that argues for deprioritizing it from the cocktail 1. Patient ecotypes such as E1 are treated as strata in gut-microbiome-ecotypes-as-patient-strata.
The NB09c cost annotation is graded rather than binary: F. plautii targeting carries the highest cost, E. bolteae targeting a moderate cost as a secondary 7α-dehydroxylation contributor, E. lenta targeting a moderate cost with a pattern the report calls partial 7α-dehydroxylation, and hungatella hathewayi / M. gnavus / E. coli targeting a low BA-coupling cost because those species are not in the 7α-dehydroxylation network in this dataset 1.
At the design-output level, Pillar 5 reports concrete cocktails for 14 of 23 patients (61 %); a pure phage cocktail is not feasible for E1, where a 3-strategy hybrid is required; the F. plautii bile-acid cost is the dominant E1 design constraint; and E. coli is present in only 35 % of the cohort 1.
A translation caveat limits all of the above: the BA-coupling cost is currently ecotype-level (NB09c §13), not per-patient, so clinical translation requires per-patient bile-acid measurements 1.
Open Directions
- Measure bai-operon gene presence across sequenced F. plautii strains to test, rather than presume, the pan-strain premise that makes the activity species-abundance-mediated 1.
- Pair per-patient bile-acid metabolomics with ecotype assignment to convert the ecotype-level BA-coupling cost into a per-patient cost usable in cocktail selection 1.
- Re-test the substrate-product signature in a cohort with recorded diet and antibiotic exposure, to separate cohort-aggregate bile-acid pool variation from the within-paired-sample mechanistic signal the narrative rests on 1.
- Repeat the Kumbhari strain-adaptation scan for E. lenta and E. bolteae, whose depletion costs NB09c rates as moderate against F. plautii’s highest, to see whether their 7α-dehydroxylation contribution is also species-abundance-mediated or instead strain-variable 2,1.